PMID- 24466441
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140624
LR  - 20220331
IS  - 2093-0879 (Print)
IS  - 2093-0887 (Electronic)
IS  - 2093-0879 (Linking)
VI  - 20
IP  - 1
DP  - 2014 Jan
TI  - New and future drug development for gastroesophageal reflux disease.
PG  - 6-16
LID - 10.5056/jnm.2014.20.1.6 [doi]
AB  - Medical therapy remains the most popular treatment for gastroesophageal reflux 
      disease (GERD). Whilst interest in drug development for GERD has declined over 
      the last few years primarily due to the conversion of most proton pump inhibitor 
      (PPI)'s to generic and over the counter compounds, there are still numerous areas 
      of unmet needs in GERD. Drug development has been focused on potent histamine 
      type 2 receptor antagonist's, extended release PPI's, PPI combination, 
      potassium-competitive acid blockers, transient lower esophageal sphincter 
      relaxation reducers, prokinetics, mucosal protectants and esophageal pain 
      modulators. It is likely that the aforementioned compounds will be niched for 
      specific areas of unmet need in GERD, rather than compete with the presently 
      available anti-reflux therapies.
FAU - Maradey-Romero, Carla
AU  - Maradey-Romero C
AD  - The Esophageal and Swallowing Center, Division of Gastroenterology and 
      Hepatology, MetroHealth Medical Center, Case Western Reserve University, 
      Cleveland, Ohio, USA.
FAU - Fass, Ronnie
AU  - Fass R
AD  - The Esophageal and Swallowing Center, Division of Gastroenterology and 
      Hepatology, MetroHealth Medical Center, Case Western Reserve University, 
      Cleveland, Ohio, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131230
PL  - Korea (South)
TA  - J Neurogastroenterol Motil
JT  - Journal of neurogastroenterology and motility
JID - 101530189
PMC - PMC3895610
OTO - NOTNLM
OT  - Erosive esophagitis
OT  - Gastroesophageal reflux
OT  - Heartburn
OT  - Proton pump inhibitors
COIS- Conflicts of interest: Ronnie Fass is a reasearcher for Mederi Therapeutics; 
      speaker for Takeda, Astrazeneca and Eisai; and a consultant for Takeda and Given 
      Imaging.
EDAT- 2014/01/28 06:00
MHDA- 2014/01/28 06:01
PMCR- 2014/01/01
CRDT- 2014/01/28 06:00
PHST- 2013/09/29 00:00 [received]
PHST- 2013/10/25 00:00 [revised]
PHST- 2013/11/09 00:00 [accepted]
PHST- 2014/01/28 06:00 [entrez]
PHST- 2014/01/28 06:00 [pubmed]
PHST- 2014/01/28 06:01 [medline]
PHST- 2014/01/01 00:00 [pmc-release]
AID - 10.5056/jnm.2014.20.1.6 [doi]
PST - ppublish
SO  - J Neurogastroenterol Motil. 2014 Jan;20(1):6-16. doi: 10.5056/jnm.2014.20.1.6. 
      Epub 2013 Dec 30.